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Abstract
The Cancer Target Discovery and Development (CTD2) Network aims to use functional
genomics to accelerate the translation of high-throughput and high-content genomic and
small-molecule data towards use in precision oncology. As part of this goal, and to share
its conclusions with the research community, the Network developed the ‘CTD2
Dashboard’ [https://ctd2-dashboard.nci.nih.gov/], which compiles CTD2 Network-
generated conclusions, termed ‘observations’, associated with experimental entities, col-
lected by its member groups (‘Centers’). Any researcher interested in learning about a
given gene, protein, or compound (a ‘subject’) studied by the Network can come to the
CTD2 Dashboard to quickly and easily find, review, and understand Network-generated
experimental results. In particular, the Dashboard allows visitors to connect experiments
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about the same target, biomarker, etc., carried out by multiple Centers in the Network.
The Dashboard’s unique knowledge representation allows information to be compiled
around a subject, so as to become greater than the sum of the individual contributions.
The CTD2 Network has broadly defined levels of validation for evidence (‘Tiers’) pertain-
ing to a particular finding, and the CTD2 Dashboard uses these Tiers to indicate the extent
to which results have been validated. Researchers can use the Network’s insights and
tools to develop a new hypothesis or confirm existing hypotheses, in turn advancing the
findings towards clinical applications.
Database URL: https://ctd2-dashboard.nci.nih.gov/
Introduction
The current Cancer Target Discovery and Development
(CTD2) initiative is a collaborative group of 13 different
research teams, or Centers, organized under the auspices of
the National Cancer Institute’s Office of Cancer
Genomics. It aims to functionally validate discoveries from
large-scale adult and pediatric cancer-genome character-
ization initiatives, and advance them towards use in preci-
sion medicine. CTD2 Centers use high-throughput
experimental and bioinformatic approaches to mine the
data and find alterations that potentially influence tumor
biology. The Network characterizes the functional roles of
candidate alterations in cancers, and identifies novel
approaches that target causative alterations through their
associated biological pathways. Through the individual
and synergistic efforts of the Centers and broad sharing of
data with the research community, CTD2 contributes to
understanding the mechanisms of cancer initiation, main-
tenance, and progression, and supports the accelerated de-
velopment of clinically useful markers, targets, and
therapeutics.
CTD2 is a ‘community resource project’ [https://www.
genome.gov/pages/research/wellcomereport0303.pdf] mean-
ing all data are openly available to the scientific community
and can be accessed without restrictions. The Network as a
whole applies a wide range of investigational approaches,
including computational biology, genome-wide loss-of-func-
tion or gain-of-function in vitro and ex vivo screening, high-
throughput small-molecule screening, and protein-protein
interaction analysis, among others. The web-based open-ac-
cess CTD2 Data Portal [https://ocg.cancer.gov/programs/
ctd2/data-portal/] is the primary outlet by which the
Network shares these diverse datasets (positive and negative
results generated as part of each Center’s research) and the
associated project descriptions and methodologies.
Although the Network has a dedicated process to harmonize
the data, a certain level of bioinformatics expertise is needed
to use the data in the Data Portal to their fullest potential.
The data in the Portal are generated with technology-
relevant controls and undergo quality assessment, but have
not been independently validated [https://ocg.cancer.gov/
sites/default/files/CTD2CaveatEmptor_final.pdf]. Therefore,
researchers who are using the data must further validate
findings in order to determine the significance and strength
of a particular result. Network results are shared through
published manuscripts, which contain data and related in-
formation. However, these data are not always provided in
an easily digestible format for all types of researcher. Such
publications concentrate on the biological relevance of a
few findings the authors find interesting, although in large-
scale high-throughput experiments, there may be many
other positive findings.
The CTD2 Dashboard [https://ctd2-dashboard.nci.nih.
gov/] addresses these data-access and usability challenges
and fills the need for a searchable and browsable web
interface that assembles concisely summarized results, con-
nects them with subsequent evidence that reinforces or
builds upon the original finding, and conveys the extent to
which the results have been functionally validated. The
Dashboard was developed to address the need of the com-
munity to find data generated by CTD2, and to adhere to
the FAIR (findable, accessible, interope rable and re-
usable) principles (1). The Dashboard was designed to
allow easy navigation and use by a range of scientists,
including both computationalists and non-computational
cancer experts.
Database structure and organization
The Dashboard concept
The CTD2 ‘Dashboard’ (which was developed by Centers
at the Broad Institute, Cold Spring Harbor Laboratories/
Memorial Sloan Kettering Cancer Center, and Columbia
University, with input from the entire CTD2 Network)
compiles CTD2 Network-generated conclusions, termed
‘observations’, associated with particular experimental
subjects. Any researcher interested in learning about a par-
ticular gene, protein, or compound that has been the
Page 2 of 10 Database, Vol. 2017, Article ID bax054
subject of experimentation by Network members can come
to the CTD2 Dashboard to quickly and easily find, review,
and download Network-generated results. In particular,
the CTD2 Dashboard allows users rapidly to connect dif-
ferent cancer biology experiments about the same biolo-
gical entity, including its function in the experiment,
carried out by multiple Centers in the Network.
Because of the diversity of data types generated by the
contributing Centers, the concept of the CTD2 Dashboard
needed to be very flexible. Indeed, one of the early concep-
tual challenges was to provide for a situation where the
types of experiments to be performed were not known in
advance. As described in detail in later sections, we ad-
dressed this challenge by defining a small number of sub-
jects that represent actual biological entities (genes,
proteins, etc.), but did not pre-define the types of data that
could be connected. Instead, we articulated a system of evi-
dence that is defined in terms of electronic data types (e.g.
numbers, text labels, images, URLs, etc.). This strategy en-
ables the CTD2 Dashboard to connect observations from
diverse types of experiments and analyses to represented
subjects (Figure 1).
To distinguish the strength of different types of evi-
dence, the CTD2 Network has developed broadly defined
Tiers of validation for evidence pertaining to a particular
finding (2). Specifically, Tier 1 evidence comprises high-
throughput biology, such as screening or profiling experi-
ments, unbiased or genome-wide computational analyses,
and other similar hypothesis-generating activities.
Evidence is classified as Tier 2 when an initial hypothesis is
validated in vitro, such as with protein-binding assays or
cell-culture models. Tier 3 evidence is supported by valid-
ation of a hypothesis in vivo, such as in mice, organoids, or
other models. Through the CTD2 Dashboard and applica-
tion of the Tier ranking system, any investigator can utilize
the Network-generated experimental results as a starting
point to extend or confirm hypotheses.
Observations–atomic units of the CTD2 Dashboard
The main challenge in developing the CTD2 Dashboard
was devising a data model capable of representing datasets
generated by the large and diverse collection of computa-
tional and experimental assays performed by the CTD2
Network Centers (Table 1). Our solution was to organize
data around the concept of an observation. Observations
are statements about biological or chemical entities (e.g.,
genes, compounds, cell lines, etc.) that concisely summar-
ize experimental results. As described above, CTD2
Dashboard observations are annotated with Tiers based on
the strength of the supporting evidence. The highest, Tier
3, is assigned to observations representing hypotheses vali-
dated in vivo. Typically, these observations correspond to
research findings reported in the literature and are the
most comprehensively validated results generated from
analysis of Network data. For example, a high-throughput
screen designed to assess how different genetic back-
grounds influence response to therapeutics could give rise
to the following observation: ‘Across many cancer types,
cell lines sensitive to BIX-01294 are enriched in cells
Figure 1. Overview of CTD2 Dashboard data types, key concepts, and web services. Items marked with (*) represent work in progress or future plans.
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harboring LYN mutations’. The italicized words in this ex-
ample highlight the building blocks of an observation,
namely the subjects, and are hyperlinked in the Dashboard
interface. The bold text ‘sensitive’ summarizes a piece of
evidence that defines the result (enrichment among sensi-
tive cell lines, in this case). Additionally, observations are
linked to background information and other evidence, i.e.,
assay-specific data which corroborate the observation
statement. For instance, for the example observation
shown above, relevant evidence could include the false dis-
covery rate, an enrichment plot and the number of cell
lines used. These CTD2 Dashboard principles are illus-
trated in more detail in subsequent sections.
Subjects–focus of the experiments
As one mission of the CTD2 Network is to discover and de-
velop new therapeutic hypotheses, we expected that
cancer-relevant genes and the proteins they encode (e.g.,
oncoproteins) would need to be explicit in our model. In
addition, perturbation reagents such as small molecules or
shRNAs, and certain common experimental systems, such
as named cell lines and mouse models, were also included.
‘Subjects’ are the focus of experiments and are categorized
into classes, such as genes, proteins, perturbagens, and
model systems. A critical first decision in conceptualizing
the CTD2 Dashboard was to decide which entities would
be considered well-defined classes for the purposes of
cross-linking different types of evidence. Together, these
subject classes form the core knowledge skeleton of the
CTD2 Dashboard, allowing researchers from multiple
Centers to connect observations and other evidence to the
same abstract entity, even when studied in separate labora-
tories. These subject names are made consistent through
vocabulary control and synonym reconciliation, ideally via
an external authority (e.g., gene names and synonyms from
HUGO Gene Nomenclature Committee database). In
some cases, such as for cell lines and mouse models, no
suitable external authority was already available, so the
CTD2 Dashboard development team curated and recon-
ciled synonyms for these subjects. This construction allows
the knowledge built around a subject to be greater than the
sum of the individual contributions.
Subject choices permit extensive connection to struc-
tured resources outside of the CTD2 Dashboard for add-
itional external data and metadata. Importantly, each
subject class warrants connection to different types of
metadata and resources. For example, genes and proteins
are described with controlled names and identifiers, and
the CTD2 Dashboard links out to other resources, includ-
ing Entrez and UniProt, which provide additional summary
information, genomic context, functional annotations,
macromolecule sequences, and references. Genes are also
linked to their monograph pages in the cBioPortal (3,4),
which provides frequencies of alteration of the gene in dif-
ferent cancer types, as well as mutation and expression-
level information in collections of samples.
Similarly, small-molecule probes and drugs can connect
to sources of outside information, as many public
databases of such entities are available (5–7). At present,
small-molecule monographs in the Dashboard link to their
corresponding entries in PubChem (7), which provide sum-
maries of activity and mechanism of action, where avail-
able, along with chemical information and descriptors,
structure representations, and links to bioactivity assays
using the compound. New versions of the Dashboard will
add links to other resources, such as the BioAssay Research
Database (8) and the Cancer Therapeutics Response Portal
(9–11), through which additional information about com-
pound activity, including in cancer cell models, can be ac-
cessed. By linking to external data about subjects whenever
possible, we enrich the CTD2 Dashboard with content be-
yond that generated explicitly by the CTD2 Network.
Roles–functions assigned to subjects based on
supporting data
Due to the diversity of experiments done by CTD2 Network
Centers and the inherent characteristic of subjects to have
multiple possible biological functions, subject classes alone
are not sufficient to provide all the contextual information
needed to understand the relationships between subjects.
Table 1. Overview of CTD2 Dashboard datasets
High-throughput or bioinformatic method # Tier 1
observations
(May 2017)
Cancer cell-line sensitivity profiling (9) 10 828
Oncogenomic screening – average
tumor volumes (18)
18
Master-regulator analyses (17,28) 38
shRNA screens and ATARiS (19,23) 6961
siRNA functional kinomics screen (21) 58
MethylMix analysis (25) 58
Elastic-net analysis of TCGA (27) 7176
Evaluation of dependency differentiality
(EDDY) analysis (20)
164
Chemical-genetic interaction mapping (24) 156
Quantitative-trait locus variant
identification (26)
19
Drug-sensitivity screening (22) 66
Reverse phase protein arrays (22) 24
Tier 1 observations associated with unique CTD2 Dashboard ‘projects’
(9,17–28) are listed for each high-throughput assay or bioinformatics ap-
proach, as of May 2017.
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We introduced additional functional classifications for sub-
jects, termed ‘roles’, which are assigned to each subject in a
CTD2 Dashboard submission to delineate how it is acting or
being used in an experiment, and to help interpret the asso-
ciated evidence. In general, roles are standardized and new
terms are added to the list of potential roles only after care-
ful consideration. This strategy prevents submitters from as-
signing very specific and unique roles to each use of a
subject, which would render the use of roles as a grouping
mechanism less effective. In the Dashboard, roles for genes
and proteins include target, biomarker, (genetic) back-
ground, interactor, (candidate) master regulator, and onco-
gene. In the Dashboard interface, a focus on targets and
biomarkers is selected by default, but users can add or re-
move roles in the Browse interface using a check-box list
under the button ‘Select Roles’. For compounds and other
perturbagens, the roles of perturbagen and (candidate) drug
are default, with an additional role of control compound
available. Finally, cell and tissue samples associated with a
particular disease context have roles of disease, metastasis,
and tissue (of origin). Roles thus allow for easier browsing
and searching.
Evidence–data supporting an observation
While subjects must conform to their type-specific con-
trolled vocabularies, submitters are allowed complete flexi-
bility when providing evidence pertinent to an observation.
This information can include numeric values or text dis-
played directly on observation pages, files (including
images) that are served by the CTD2 Dashboard’s web-
server, or URL hyperlinks to other websites. Thus, CTD2
Dashboard evidence is constrained and categorized not by
its biological meaning or context, but rather by its electronic
data type. Furthermore, to indicate how a particular piece
of evidence was obtained, we categorize them as ‘observed’,
‘measured’, or ‘computed’. Again, these classifications are
more general than any particular biological context or inter-
pretation, and together these broad evidence types and cate-
gories encourage submitters to define evidence in new and
creative ways. Each of the existing Dashboard evidence
types and roles are mapped to their corresponding Evidence
Ontology (http://www.evidenceontology.org/) codes and ap-
propriate hyperlinks are provided to the corresponding
Evidence Ontology pages. Furthermore, we encourage sub-
mitters to use Evidence Ontology terms in their submissions
to provide further resolution of classes of evidence.
Data submissions and curation
Data submitted to the Dashboard by CTD2 Network
Centers can be accessed through the web interface [https://
ctd2-dashboard.nci.nih.gov/]. The primary goal of the
interface is to enable inter-connecting, browsing, search-
ing, and presentation of the CTD2 Dashboard data
through a front-end that is intuitive to use and accessible
to scientists at all levels of bioinformatics expertise. A key
element that enables this functionality is the consistent use
of controlled subject classes across all Center submissions.
These serve as unambiguous identifiers that facilitate
cross-referencing of data from different Centers to identify
observations referring to the same abstract biological
entities.
The CTD2 Dashboard is geared towards sharing obser-
vations with scientists and others not specializing in com-
putational biomedicine (Figure 1). New content is
contributed to the CTD2 Dashboard through individual
‘submissions’ by the CTD2 Network Centers. A submis-
sion is a collection of observations that were obtained
from one investigation, possibly integrating more than one
type of experiment, and whose results share the same
structure and format. For functional biology experiments
(Tiers 2 and 3), submissions often consist of only a single
observation. Currently the process of preparing, curating,
and uploading submissions is manual. Submitters, with
the help of the CTD2 Dashboard team, identify fields (sub-
jects, background information, and evidence) pertinent to
observations, assign classes, roles, and types to the fields,
and provide, in a tabular file format, descriptive text for
each field displayed on the corresponding observation
page. A submission must contain an ‘observation sum-
mary’ that describes each observation and is displayed on
browse and search pages. These summaries use variables
(i.e., subject classes that are ‘filled in’ by the submitting
Center) and additional text to provide context for inter-
linking subjects appropriately. Multiple observations of
the same type (e.g., describing multiple results from a cer-
tain experiment or analysis), but about different subjects
of the same class, can be handled by a single observation
summary. Prior to loading to the CTD2 Dashboard, sub-
missions are automatically checked for internal consist-
ency and for consistency with current CTD2 Dashboard
content. Recently, the CTD2 Dashboard team created a
web-based submission-generation system to guide con-
tributors through the process. To manage quality control,
at this time only CTD2 Network Centers can contribute
new submissions to the Dashboard. However, we envision
that this system may open the door for future Dashboard
submissions from outside the CTD2 Network. To keep
users up-to-date on the latest additions to the Dashboard,
an RSS feed feature is provided, which allows subscribtion
to receive a notification of submissions or observations
involving a subject of interest (e.g., gene, protein, or
compound).
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Contextual architecture is independent of subject
matter
The fundamental structure of the CTD2 Dashboard archi-
tecture is not coupled to cancer targets, cancer biology, or
even biology. Indeed, any system of controlled subject
names could serve as a knowledge skeleton for attaching
evidence. We have not fully explored alternative knowledge
domains beyond the conceptual stage, but certainly encour-
age others to do so. Controlled-name subjects with any
entity-relational framework could be coupled with evidence
classes used in the current CTD2 Dashboard: labels, nu-
meric values, URLs, images, and attached files. In this
sense, the CTD2 Dashboard serves as a way to link an
‘operating system’ of file types with each member subject of
a given class. In other words, the Dashboard does not need
to understand the contents of the evidence being linked,
only the format in which that evidence is being presented.
User interface
The end-user-facing web application is constructed in two
layers. The back-end is implemented as a series of RESTful
web services based on the Spring framework, a widely used
application framework and inversion-of-control container
for the Java platform [https://spring.io/guides/gs/rest-ser
vice/]. The front-end is developed using the lightweight
backbone.js JavaScript library [http://backbonejs.org/docs/
backbone.html]. The design provides a loose and flexible
coupling between the two layers, allowing for each part to
be developed and maintained independently from the
other. The database supporting the CTD2 Dashboard web
interface is built using the Hibernate implementation of
the Java Persistence API, which is seamlessly supported by
the Spring framework. The back-end RDBMS used is
MySQL. The CTD2 Dashboard source code is open and
publicly available on GitHub [https://github.com/CBIIT/
nci-ctd2-dashboard/].
Researchers who visit the CTD2 Dashboard to investi-
gate a specific gene or compound will find the Search func-
tion to be the most expedient method for locating relevant
data. CTD2 Dashboard data are indexed against subject
terms and can be queried using the search box located in
the top menu bar of the CTD2 Dashboard. For instance,
searching for a full or partial gene symbol will generate a
list of all matching genes along with a count of the obser-
vations involving each gene; each count is hyperlinked to a
detailed list of the relevant observations.
In addition to search, data can be explored via several
browsing options.
• Subject-based browsing: Exploration of CTD2
Dashboard entries can be initiated from a summary
view. The CTD2 Dashboard offers three “Browse” pages
focusing on genes, compounds, and cancer types. Each
page provides a list of biological entities prioritized ac-
cording to the number, breadth, and level of validation
of the observations involving those entities. For example,
the ‘Biomarkers, Targets, Genes & Proteins’ browse
page focuses on genes and lists roles and observations
associated with each subject (Figure 2). Users can down-
load this table as an Excel file using the function called
“Export as Spreadsheet”.
• Submission-based browsing: The ‘Centers’ link at the
site’s top navigation bar leads to a page that lists all the
CTD2 Network Centers. From that list, users can access
all data submissions produced by a Center and drill
down to the observation data in each submission. There
is also a link which allows the user to easily and directly
download the entire submission source data package.
• Story-based browsing: Research findings that have been
explored in detail are featured prominently on the home-
page of the CTD2 Dashboard in the form of stories. The
aim of stories is to distill the essential elements of re-
ported results, including integration of many experi-
ments at different levels of evidence, at a level of detail
that is appropriate for a general scientific audience.
Search and browse operations ultimately result in a list
of entry points to detailed information about observations
and subjects. For instance, clicking on any gene symbol
under the ‘Name’ column in the gene-browser list leads to
a gene profile page (Figure 3) where the top portion con-
tains key gene descriptors and links to relevant annotations
and resources, and the bottom portion lists the observa-
tions generated by the Centers involving that gene. As with
the browse feature, users can download this entire table as
an Excel file using the button ‘Export to Spreadsheet’.
Similarly, clicking on the ‘details’ link of any observation
brings up a page (Figure 4) describing the observation attri-
butes, including:
• a short summary of the related investigational finding
(i.e., the observation summary);
• the biological entities (genes, compounds, cell lines, etc.)
involved in the study and their specific roles;
• description of the submission, submission date, and a
link to download all the data (evidence) associated with
that submission;
• experimentally and computationally derived evidence
supporting the reported finding.
Gene Cart
Many CTD2 Dashboard pages contain green ‘þ’ icons ad-
jacent to gene symbols (see Figures 3 and 4). During
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Figure 3. Example gene-profile page. Gene-profile page for PIK3CB shows synonyms (as defined by Entrez), provides links to external annotation
web sites, and lists observations involving PIK3CB along with their Tiers and the submitting Center names. Similar detail pages are available for all
subject types supported by the CTD2 Dashboard.
Figure 2. ‘Biomarkers, Targets, Genes & Proteins’ browse page. Every table row corresponds to a gene–role pair, and displays for each evidence Tier
the number of observations where the gene has been reported to play the specific role. The number of Centers who have contributed towards the ob-
servations is also shown. The ‘Select Roles’ button can be used to customize this view by adding or removing roles beyond those used in the default
listing (‘biomarker’ and ‘target’). The initial ordering of the table rows is determined by a relevance score calculated as the sum across Centers of the
highest Tier evidence provided by each Center contributing evidence.
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Dashboard data exploration, users can click on these icons
to incrementally compile a list of genes of interest. This list
can be accessed through the ‘Gene Cart’ link available in
CTD2 Dashboard’s navigation menu (Figure 5a). From
there, users are able to edit the contents of the list and to
query the Cellular Networks Knowledge Base (CNKB)
(12) repository of molecular interaction networks to
retrieve interactions involving the genes in the Gene Cart
(Figure 5b and c). CNKB (12) is a database of protein and
gene interactions maintained at Columbia University. It
comprises curated pathway collections and cancer tissue-
specific regulatory and signaling networks derived compu-
tationally through the analysis of large gene-expression
datasets (13) such as those generated by The Cancer
Genome Atlas, and also predicted or measured protein-
protein interactions (14,15). The ability to interrogate
CNKB and to explore the interactions involving key tumor
regulators can help users better contextualize and interpret
Dashboard observations. For instance, if an shRNA screen
reduces the viability of a tumor cell line, looking at the
interaction network involving the shRNA targets may re-
veal the underlying mechanism of action by identifying
genes regulated by these targets.
Discussion
As content continues to grow and submitters continue to
find creative uses for the Dashboard as a data-sharing plat-
form, the CTD2 Dashboard team will continue to improve
the database and interface (Figure 1). Our current major
undertaking to improve CTD2 Dashboard functionality is
creating a web-based submission-generation system that
uses standardized formats, thereby reducing the time and
complexity of the submission process by automating data
import and validation. Plans to improve the user experience
and further enrich the content include linking to additional
outside resources that the Network selects as useful. For ex-
ample, on the gene-entry pages, hyperlinks will point users
Figure 4. Example observation page. This page comprises an observation summary, a list of implicated subjects, a download link to information
about the data submission containing the observation, and the evidence supporting the observation findings.
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to GeneCards and HGNC. The ‘Compounds &
Perturbagens’ browse pages will include links to ChemBank
(6,16), BioAssay Research Database (8), and ZINC (5).
Links to relevant cell lines at American Type Culture
Collection (ATCC) will be added to the tissue-type entries.
In keeping with the FAIR principles (1), further evolution
of the Dashboard will continue to expand the use of cross-
links with other community resources.
As CTD2 Dashboard content grows, evidence to sup-
port higher-Tier rankings increases, and additional exter-
nal resources are integrated, the opportunities for its use
will expand. Already, many Dashboard submissions about
the same subjects are interconnected across multiple Tiers,
reflecting the evolving validation within CTD2 Network
projects. The wealth of information embedded in the
CTD2 Dashboard can be taken advantage of to confirm
hypotheses and initiate new collaborations. We plan to
take advantage of this information to explore new bio-
informatic analyses that may yield new cancer dependen-
cies. We encourage the research community to use this
database to study the experimental approaches the
Network has taken, explore the data using an easily
minable format, develop new hypotheses, and build on
CTD2 Network findings.
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Figure 5. The CTD2 Dashboard Gene Cart feature. (a) The ‘Gene Cart’ link available on the top navigation bar leads to a page that lists all genes that
have been added by the user. From this page, users can add or remove genes from the list and initiate a query of the Cellular Networks Knowledge
Base. (b) After selecting interactome type and version (in this example, B-Cell Interactome v1.0 was chosen) query results are summarized in a tabular
view, with one row per query gene. Each row shows the number of interactions involving the corresponding gene, categorized according to inter-
action type (protein–DNA or protein–protein). Results can be exported as a SIF format file for display in third-party software such as Cytoscape
(29,30). (c) Users can also select one or more of the query genes and click on the ‘Create Network’ link to generate a graph view of the interactions.
Nodes in yellow represent query genes. Edges represent interactions and are colored according to the type of interaction.
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